



Rec'd PCT/PTO 15 AUG 2001 #3 #6/B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Box PCT
UEMURA et al)	Examiner:
Appln. No.: 09/856,319)	Washington, D.C.
IA No.: PCT/JP99/06473)	
IA Filed: November 19, 1999)	August 15, 2001
For: NOVEL SERINE PROTEASE BSSP5))	Atty.Docket: UEMURA=5

RESPONSE TO NOTIFICATION TO COMPLY WITH
SEQUENCE LISTING REQUIREMENTS

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notification to Comply dated June 22, 2001, and prior to the examination of the above-described application, please amend the present application as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 22, line 24 and ending at page 24, line 4, with the following rewritten paragraph:

--The vector is not specifically limited in so far as it can express the protein of the present invention. Examples thereof include pBAD/His, pRSETA, pcDNA2.1, pTrcHis2A, pYES2, pBlueBac4.5, pcDNA3.1 and pSecTag2 manufacture by Invitrogen, pET and pBAC manufactured by Novagen, pGEM manufactured by Promega, pBluescriptII manufactured by Stratagene, pGEX and pUC18/19 manufactured by

09856319-052101

B